George Trainor, PhD
Dr. Trainor brings 30 years of experience in the biotechnology and pharmaceutical Industries to TamRx. He has expertise in overall drug discovery strategy and execution, medicinal chemistry, and the application of transformative technologies. Leading teams of over 100 scientists, he has advanced over 35 drug candidates into clinical development in a diverse spectrum of therapeutic areas including antivirals, cancer, neuroscience, and inflammation. His team provided key discovery support that enabled the successful launch of SustivaTM for HIV disease.
Dr. Trainor has previously held roles at Bristol Myers Squibb Company, where he was the Vice President of Oncology and Early Discovery Chemistry, and Dupont/Dupont Merck Pharmaceuticals, where he was the Executive Director for Medicinal Chemistry. His key contribution from that period was the discovery and commercial development of fluorescence-tagged chain terminators for use in automated DNA sequencing, which was subsequently employed in the sequencing of the human genome. In 2011, Trainor won the American Chemical Society’s Heroes of Chemistry Award for his work on DNA sequencing. Dr. Trainor is an inventor on nearly 20 issued US patents, and has over 80 peer-reviewed publications. He has served on Grant Review Study Sections for the NIH and DOE. Dr. Trainor received his PhD in Organic Chemistry at Harvard University, and was an NIH Postdoctoral Fellow at Columbia University.